Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Waldenstrom Macroglobulinemia × Lisaftoclax × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Neuroblastoma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1

Interventions

Rituximab 16 ibrutinib 9 Bortezomib 8 fludarabine phosphate 7 Lenalidomide 6 Cyclophosphamide 5 Bendamustine Hydrochloride 5 Peripheral Blood Stem Cell Transplantation 4 Flow Cytometry 4 Dasatinib 4 tanespimycin 3 pomalidomide 3 belinostat 3 Vorinostat 3 Polymerase Chain Reaction 3 Pharmacogenomic Testing 3 Melphalan 3 Everolimus 3 Etoposide 3 Dexamethasone 3 ublituximab 2 nelarabine 2 ibritumomab tiuxetan 2 fludarabine 2 carfilzomib 2 alvocidib 2 Tacrolimus 2 Methotrexate 2 Magnetic Resonance Spectroscopy 2 MLN 8237 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04260217 2025-08-19

MAPLE-1

Ascentage Pharma Group Inc.

Phase 1 Completed

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡